J

Johnson & Johnson

Makes prescription drugs and medical devices

Plan Systems Integration Sr Analyst

Full-TimeUpdated Deadline 11/3/26
$94k - $151.8k+ Long-term incentive program
Mid, Senior
Master's, MBA
Raritan, NJ, USA
HybridHybrid work in Raritan; requires 20–30% international travel.
IT OperationsIT Project Management

About the job

Requirements
  • A master’s degree in Engineering, Supply Chain, Business Administration, Operations, or equivalent is required; an MBA is preferred.
  • At least 5 years of progressive leadership experience in Operations, Supply Chain, or major transformation programs.
  • At least 3–4 years of experience in planning functions.
  • Strong knowledge of MedTech supply chain and planning systems, such as OMP, APO, Blue Yonder, and Demantra; OMP experience is highly preferred.
  • Experience as part of a deployment team on global or local programs in distributed environments.
  • In-depth planning experience and in-depth knowledge of planning systems, with OMP highly preferred.
  • Ability to navigate and operate within complex, multi-system environments.
  • Hands-on project delivery experience, including timeline management and cross-functional coordination.
  • Strong stakeholder management skills across senior leaders, vendors, and partners.
  • Ability to persuade and influence in sensitive and complex situations.
  • Deep understanding of end-to-end supply chain processes and functional interdependencies.
  • Global experience with diverse teams, cultures, and matrix organizations.
  • Strong analytical, quantitative, communication, and presentation capabilities.
Responsibilities
  • Lead and execute multiple waves of integration between Transcend S/4 OTC and planning systems (APS), including design, build, testing, training, cutover, and go-live activities.
  • Collaborate with Business SMEs, Product Owners, JJT, OMP, S/4, PLAN BPO, and business stakeholders to drive day-to-day operations and maintain effective cadences.
  • Ensure strong alignment with business units and central functions.
  • Manage relationships with external vendors and integrators, including planning and resource management.
  • Provide stakeholders with frequent updates on decisions, progress, risks, and key issues.
  • Lead operational program delivery, including managing team performance, schedules, and cross-functional execution.
  • Ensure all User Stories and KDDs in JIRA for Global Template processes are fully solutioned, tested, and successfully deployed.
  • Create and maintain training materials and deliver training across the planning community to support business adoption.
  • Lead and coordinate project managers and indirect or external resources to deploy the program.
  • Build alignment and collaboration with partner functions, including J&J Technology, MT SC Digital, Commercial, Business Unit Supply Chain, and Integrated Business Management.
Desired Qualifications
  • MBA.
  • OMP experience.
  • FPX PL, PMP, or SME certification.
  • APICS or Lean Six Sigma certification.
  • Expertise in supply chain planning systems and advanced planning systems, through operational experience, business analysis during a planning system implementation, or Business SME/change impact assessment; OMP is preferred, and SAP APO, Kinaxis, or Blue Yonder experience is also relevant.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.